Supporting Information

Functional profiling of adenylation domains in nonribosomal peptide synthetases

by competitive activity-based protein profiling

Shota Kasai, Sho Konno, Fumihiro Ishikawa,* and Hideaki Kakeya*

Department of System Chemotherapy and Molecular Sciences, Division of Bioinformatics and Chemical Genomics, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto 606-8501, Japan

*Correspondence and request for materials should be directed via email to F. Ishikawa (fishika@pharm.kyoto-u.ac.jp) or H. Kakeya (seseigyo-hisyo@pharm.kyoto-u.ac.jp).

#These authors contributed equally to this work.
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Figure S1</td>
<td>S3</td>
</tr>
<tr>
<td>Supplementary Figure S2</td>
<td>S4</td>
</tr>
<tr>
<td>Supplementary Figure S3</td>
<td>S5</td>
</tr>
<tr>
<td>Supplementary Figure S4</td>
<td>S6</td>
</tr>
<tr>
<td>Supplementary Figure S5</td>
<td>S7</td>
</tr>
<tr>
<td>Supplementary Figure S6</td>
<td>S8</td>
</tr>
<tr>
<td>Supplementary Figure S7</td>
<td>S9</td>
</tr>
<tr>
<td>Supplementary Figure S8</td>
<td>S9</td>
</tr>
<tr>
<td>Supplementary Figure S9</td>
<td>S10</td>
</tr>
<tr>
<td>Supplementary Figure S10</td>
<td>S10</td>
</tr>
<tr>
<td>Supplementary Figure S11</td>
<td>S10</td>
</tr>
<tr>
<td>Supplementary Figure S12</td>
<td>S11</td>
</tr>
<tr>
<td>Supplementary Figure S13</td>
<td>S11</td>
</tr>
<tr>
<td>Supplementary Figure S14</td>
<td>S12</td>
</tr>
<tr>
<td>Supplementary Figure S15</td>
<td>S13</td>
</tr>
<tr>
<td>Supplementary Figure S16</td>
<td>S14</td>
</tr>
<tr>
<td>Supplementary Figure S17</td>
<td>S15</td>
</tr>
<tr>
<td>Supplementary Figure S18</td>
<td>S16</td>
</tr>
<tr>
<td>Supplementary Figure S19</td>
<td>S17</td>
</tr>
<tr>
<td>Supplementary Figure S20</td>
<td>S18</td>
</tr>
<tr>
<td>Supplementary Figure S21</td>
<td>S19</td>
</tr>
<tr>
<td>Supplementary Figure S22</td>
<td>S20</td>
</tr>
<tr>
<td>Supplementary Figure S23</td>
<td>S21</td>
</tr>
<tr>
<td>Supplementary Table S1</td>
<td>S22</td>
</tr>
<tr>
<td>Supplementary Table S2</td>
<td>S22</td>
</tr>
<tr>
<td>Supplementary Table S3</td>
<td>S23</td>
</tr>
<tr>
<td>Supplementary Table S4</td>
<td>S23</td>
</tr>
<tr>
<td>Supplementary Table S5</td>
<td>S24</td>
</tr>
<tr>
<td>Supplementary Table S6</td>
<td>S25</td>
</tr>
<tr>
<td>Supplementary Table S7</td>
<td>S25</td>
</tr>
<tr>
<td>Supplementary Scheme S1</td>
<td>S26</td>
</tr>
<tr>
<td>Chemical Synthetic Procedures</td>
<td>S26-S45</td>
</tr>
<tr>
<td>Chemical Biology Procedures</td>
<td>S45-S48</td>
</tr>
<tr>
<td>References</td>
<td>S49</td>
</tr>
<tr>
<td>Copies of $^1$H-NMR and $^{13}$C-NMR spectra</td>
<td>S50-S79</td>
</tr>
</tbody>
</table>
Figure S1. Nonribosomal peptide synthesis of the antibiotic gramicidin S. Modules are comprised of thiolation (T), adenylation (A) [A1: L-Phe; A2: L-Pro; A3: L-Val; A4: L-Orn; A5: L-Leu specific A-domains], epimerization (E), condensation (C), and thioesterase (TE) domains.
Figure S2. Full images of SDS-PAGE gels from Figure 3a. Competitive ABPP of 6–25 towards the A-domain of endogenous GrsA. Assessment of the inhibition potency (100 µM compound) in the *A. migulanus* ATCC 9999 proteome with probe 1 (1 µM). The top image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm and the bottom (Σ) denotes total protein content by staining with Coomassie (Colloidal Coomassie Blue Stain).
Figure S3. Full images of SDS-PAGE gels from Figure 3b. Competitive ABPP of 6–25 towards the A-domain of endogenous GrsA. Dose–response competitive ABPP experiments to assess the selectivity of (a) 6, (b) 12, (c) 18, (d) 20, and (e) 25 towards the A-domain of GrsA in the *A. migulanus* ATCC 9999 proteome with probe 1 (1 µM). The image (Φ) depicts the fluorescence observed with λ<sub>ex</sub> = 532 nm and λ<sub>em</sub> = 580 nm.
Figure S4. Competitive ABPP of 17 and 23 towards the A-domain of endogenous GrsA. Dose–response competitive ABPP experiments to assess the selectivity of (a) 17 and (b) 23 towards the A-domain of GrsA in the *A. migulanus* ATCC 9999 proteome with probe 1. The *A. migulanus* ATCC 9999 lysate (2.0 mg/mL) was pre-incubated with inhibitors 17 and 23 (10 nM to 1 mM) before the addition of 1 µM of probe 1. The image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm.
Figure S5. Competitive ABPP of 6–25 towards the A-domain of recombinant GrsA. Assessment of the inhibition potency (100 µM compound) in the A-domain of GrsA (1 µM) with probe 1 (1 µM). The top image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm and the bottom (Σ) denotes total protein content by staining with Coomassie (Colloidal Coomassie Blue Stain).
Figure S6. Competitive ABPP of 6, 12, 18, 20, 25, 17, and 23 towards the A-domain of recombinant GrsA. Dose–response competitive ABPP experiments to assess the selectivity of (a) 6, (b) 12, (c) 18, (d) 20, (e) 25, (f) 17, and (g) 23 towards the A-domain of GrsA with probe 1. Recombinant GrsA (1 μM) was pre-incubated with inhibitors 6 (1 nM to 100 μM), 12 (10 nM to 1 mM), 18 (10 nM to 1 mM), 20 (10 nM to 1 mM), 25 (10 nM to 1 mM), 17 (10 nM to 1 mM), and 23 (10 nM to 1 mM) before the addition of 1 μM of probe 1. The image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm.
Figure S7. Steady-state kinetics of GrsA with L-Phe. Each reaction contained 50 nM holo-GrsA, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl₂, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase, 0.04 U inorganic pyrophosphatase, 0.2 mM MesG, and 6.25–1000 µM L-Phe.

Figure S8. Steady-state kinetics of GrsA with L-Leu. Each reaction contained 700 nM holo-GrsA, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl₂, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase, 0.04 U inorganic pyrophosphatase, 0.2 mM MesG, and 0.625–10 mM L-Leu.
Figure S9. Steady-state kinetics of GrsA with L-Thr. Each reaction contained 1.4 µM holo-GrsA, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl$_2$, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase, 0.04 U inorganic pyrophosphatase, 0.2 mM MesG, and 25–300 mM L-Thr.

Figure S10. Steady-state kinetics of GrsA with L-Met. Each reaction contained 140 nM holo-GrsA, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl$_2$, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase, 0.04 U inorganic pyrophosphatase, 0.2 mM MesG, and 2.5–100 mM L-Met.
**Figure S11. Steady-state kinetics of GrsA with L-Trp.** Each reaction contained 700 nM holo-GrsA, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl$_2$, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase, 0.04 U inorganic pyrophosphatase, 0.2 mM MesG, and 0.125–2.0 mM L-Trp.

![Graph](image1)

**Figure S12. Steady-state kinetics of GrsA with L-His.** Each reaction contained 1.4 µM holo-GrsA, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl$_2$, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase, 0.04 U inorganic pyrophosphatase, 0.2 mM MesG, and 3.125–100 mM L-His.

![Graph](image2)

**Figure S13. Steady-state kinetics of TycB1 with L-Pro.** Each reaction contained 400 nM holo-TycB1, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl$_2$, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase, 0.04 U inorganic pyrophosphatase, 0.2 mM MesG, and 10–2000 µM L-Pro. Velocities were fit to the Michaelis-Menten equation.

![Graph](image3)
Figure S14. Full images of SDS-PAGE gels from Figure 4a. Competitive ABPP of 6–25 toward the A-domains of endogenous GrsB in the *A. migulanus* ATCC 5759 proteome. Assessment of the inhibition potency (100 µM compound) towards the Pro-activating domain of GrsB with probe 2 (1 µM). The top image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm and the bottom (Σ) denotes total protein content by staining with Coomassie (Colloidal Coomassie Blue Stain).
Figure S15. Dose–response competitive ABPP of 7, 8, and 15 towards the Pro-activating domain of endogenous GrsB. The *A. migulanus* DSM 5759 lysate (2.0 mg/mL) was pre-incubated with 7 (0.01 nM to 10 µM), 8 (0.1 to 1000 µM), and 15 (0.1 to 1000 µM) before the addition of 1 µM of probe 2. The image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm.
Figure S16. Competitive ABPP of 6–25 toward the A-domains of recombinant TycB1. Assessment of the inhibition potency (100 µM compound) towards the Pro-activating domain of TycB1 (1 µM) with probe 2 (1 µM). The top image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm and the bottom (Σ) denotes total protein content by staining with Coomassie (Colloidal Coomassie Blue Stain).
Figure S17. Competitive ABPP of 7, 8, and 15 towards the Pro-activating domain of recombinant TycB1. Dose–response competitive ABPP experiments to assess the selectivity of (a) 7, (b) 8, and (c) 15 towards the A-domain of TycB1 with probe 2. Recombinant TycB1 (1 µM) was pre-incubated with inhibitors 7 (1 nM to 100 µM), 8 (0.1 µM to 1000 µM), and 15 (0.1 µM to 1000 µM) before the addition of 1 µM of probe 2. The image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm.
Figure S18. Full images of SDS-PAGE gels from Figure 4b. Competitive ABPP of 6–25 toward the A-domains of endogenous GrsB in the *A. migulanus* ATCC 5759 proteome. Assessment of the inhibition potency (100 µM compound) towards the Orn-activating domain of GrsB with probe 3 (1 µM). The top image (Φ) depicts the fluorescence observed with $\lambda_{\text{ex}} = 532$ nm and $\lambda_{\text{em}} = 580$ nm and the bottom (Σ) denotes total protein content by staining with Coomassie (Colloidal Coomassie Blue Stain).
Figure S19. Dose–response competitive ABPP of 8, 15, 23, and 24 towards the Orn-activating domain of endogenous GrsB. The A. migulanus DSM 5759 lysate (2.0 mg/mL) was pre-incubated with (a) 8, (b) 15, (c) 23, and (d) 24 at concentrations ranging from 0.1 pM to 1 mM (8: 0.1 pM to 100 nM; 15: 100 nM to 1 mM; 23: 100 nM to 1 mM; 24: 100 nM to 1 mM) before the addition of 1 µM of probe 3. The image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm.
**Figure S20.** Full images of SDS-PAGE gels from Figure 4c. Competitive ABPP of 6–25 toward the A-domains of endogenous GrsB in the *A. migulanus* ATCC 5759 proteome. Assessment of the inhibition potency (100 µM compound) towards the Val-activating domain of GrsB with probe 4 (1 µM). The top image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm and the bottom (Σ) denotes total protein content by staining with Coomassie (Colloidal Coomassie Blue Stain).
Figure S21. Dose–response competitive ABPP of 11, 12, 13, 18, 20, and 25 towards the Val-activating domain of endogenous GrsB. The *A. migulanus* DSM 5759 lysate (2.0 mg/mL) was pre-incubated with (a) 11, (b) 12, (c) 13, (d) 18, (e) 20, and (f) 25 at concentrations ranging from 0.1 nM to 100 µM (11: 0.1 nM to 100 µM; 12: 100 nM to 100 µM; 13: 100 nM to 100 µM; 20: 100 nM to 100 µM; 25: 100 nM to 100 µM) before the addition of 1 µM of probe 4. The image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm.
Figure S22. Full images of SDS-PAGE gels from Figure 4d. Competitive ABPP of 6–25 toward the A-domains of endogenous GrsB in the *A. migulanus* ATCC 5759 proteome. Assessment of the inhibition potency (100 µM compound) towards the Leu-activating domain of GrsB with probe 5 (1 µM). The top image (Φ) depicts the fluorescence observed with $\lambda_{ex} = 532$ nm and $\lambda_{em} = 580$ nm and the bottom (Σ) denotes total protein content by staining with Coomassie (Colloidal Coomassie Blue Stain).
Figure S23. Dose–response competitive ABPP of 10, 12, and 18 toward the Leu-activating domain of endogenous GrsB. The *A. migulanus* DSM 5759 lysate (2.0 mg/mL) was pre-incubated with (a) 12, (b) 18, and (c) 10 at concentrations ranging from 0.1 nM to 1 mM (12: 0.1 nM to 100 µM; 18: 100 nM to 100 µM; 10: 100 nM to 100 µM) before the addition of 1 µM of probe 5. The image (Φ) depicts the fluorescence observed with λ<sub>ex</sub> = 532 nm and λ<sub>em</sub> = 580 nm.
Table S1. Catalytic parameters of the adenylation reaction catalyzed by the A-domain of GrsA.[a]

<table>
<thead>
<tr>
<th>substrate</th>
<th>$k_{cat}$ [min$^{-1}$]</th>
<th>$K_m$ [mM]</th>
<th>$k_{cat}/K_m$ [mM$^{-1}$ min$^{-1}$]</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-Phe</td>
<td>500 ± 12</td>
<td>0.0248 ± 0.0023</td>
<td>20161 ± 5217</td>
</tr>
<tr>
<td>L-Leu</td>
<td>5.09 ± 0.40</td>
<td>2.85 ± 0.57</td>
<td>1.79 ± 0.71</td>
</tr>
<tr>
<td>L-Thr</td>
<td>2.51 ± 0.39</td>
<td>246 ± 69</td>
<td>0.011 ± 0.0007</td>
</tr>
<tr>
<td>L-Met</td>
<td>35.8 ± 2.1</td>
<td>18.5 ± 3.3</td>
<td>1.92 ± 0.17</td>
</tr>
<tr>
<td>L-Trp</td>
<td>5.98 ± 0.43</td>
<td>1.49 ± 0.19</td>
<td>4.02 ± 2.2</td>
</tr>
<tr>
<td>L-His</td>
<td>1.56 ± 0.09</td>
<td>17.5 ± 3.0</td>
<td>0.089 ± 0.0037</td>
</tr>
</tbody>
</table>

[a] Catalytic parameters were determined by a coupled hydroxamate-MesG continuous spectrophotometric assay. [b] not detected.

Table S2. Catalytic parameters of the adenylation reaction catalyzed by the A-domain of TycB1.[a]

<table>
<thead>
<tr>
<th>substrate</th>
<th>$k_{cat}$ [min$^{-1}$]</th>
<th>$K_m$ [µM]</th>
<th>$k_{cat}/K_m$ [mM$^{-1}$ min$^{-1}$]</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-Pro</td>
<td>6.36 ± 0.28</td>
<td>125 ± 24</td>
<td>50.8 ± 11.6</td>
</tr>
</tbody>
</table>

[a] Catalytic parameters were determined by a coupled hydroxamate-MesG continuous spectrophotometric assay. Comprehensive analysis of relative substrate specificities of the homologous A-domain within the first module of TycB (TycB1) have revealed that it exhibited strict substrate specificities and activated exclusively the cognate substrate L-Pro within the 10 amino acid substrates tested. [2]
Table S3. Dose–response competitive ABPP experiments to assess the selectivity of 6, 12, 18, 20, and 25 towards the A-domains of endogenous and recombinant GrsA.

<table>
<thead>
<tr>
<th>cpd</th>
<th>structure</th>
<th>( \text{IC}_{50} (\mu \text{M}) )</th>
<th>endogenous GrsA</th>
<th>recombinant GrsA</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td><img src="image1" alt="Structure" /></td>
<td>0.38 ± 0.14</td>
<td>0.24 ± 0.04</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td><img src="image2" alt="Structure" /></td>
<td>23.0 ± 0.12</td>
<td>10.0 ± 0.11</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td><img src="image3" alt="Structure" /></td>
<td>27.2 ± 0.22</td>
<td>9.86 ± 0.09</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td><img src="image4" alt="Structure" /></td>
<td>9.90 ± 0.13</td>
<td>1.51 ± 0.20</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td><img src="image5" alt="Structure" /></td>
<td>126 ± 0.18</td>
<td>49.9 ± 0.27</td>
<td></td>
</tr>
</tbody>
</table>

Table S4. Dose–response competitive ABPP experiments to assess the selectivity of 7 towards the Pro-activating domains of endogenous GrsB and recombinant TycB1.

<table>
<thead>
<tr>
<th>cpd</th>
<th>structure</th>
<th>( \text{IC}_{50} (\mu \text{M}) )</th>
<th>endogenous GrsB</th>
<th>recombinant TycB1</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td><img src="image6" alt="Structure" /></td>
<td>0.29 ± 0.09</td>
<td>0.69 ± 0.20</td>
<td></td>
</tr>
</tbody>
</table>
Table S5. Dose–response competitive ABPP experiments to assess the selectivity of 8, 15, 23, and 24 towards the Orn-activating domain of endogenous GrsB.

<table>
<thead>
<tr>
<th>cpd</th>
<th>structure</th>
<th>IC(_{50}) endogenous GrsB</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td><img src="image" alt="Structure 8" /></td>
<td>18.5 ± 2.6 (nM)</td>
</tr>
<tr>
<td>15</td>
<td><img src="image" alt="Structure 15" /></td>
<td>139 ± 0.33 (µM)</td>
</tr>
<tr>
<td>23</td>
<td><img src="image" alt="Structure 23" /></td>
<td>8.2 ± 0.14 (µM)</td>
</tr>
<tr>
<td>24</td>
<td><img src="image" alt="Structure 24" /></td>
<td>4.6 ± 0.15 (µM)</td>
</tr>
</tbody>
</table>
Table S6. Dose–response competitive ABPP experiments to assess the selectivity of 11, 12, 13, 18, 20, and 25 towards the Val-activating domain of endogenous GrsB.

<table>
<thead>
<tr>
<th>cpd</th>
<th>structure</th>
<th>IC$_{50}$ (µM)</th>
<th>endogenous GrsB</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td><img src="image1" alt="structure" /></td>
<td>0.11 ± 0.04</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td><img src="image2" alt="structure" /></td>
<td>2.8 ± 0.23</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td><img src="image3" alt="structure" /></td>
<td>6.0 ± 0.10</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td><img src="image4" alt="structure" /></td>
<td>0.42 ± 0.08</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td><img src="image5" alt="structure" /></td>
<td>0.65 ± 0.04</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td><img src="image6" alt="structure" /></td>
<td>2.2 ± 0.28</td>
<td></td>
</tr>
</tbody>
</table>

Table S7. Dose–response competitive ABPP experiments to assess the selectivity of 12 and 18 towards the Leu-activating domain of endogenous GrsB.

<table>
<thead>
<tr>
<th>cpd</th>
<th>structure</th>
<th>IC$_{50}$</th>
<th>endogenous GrsB</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td><img src="image7" alt="structure" /></td>
<td>1.7 ± 0.09 nM</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td><img src="image8" alt="structure" /></td>
<td>2.7 ± 0.22 µM</td>
<td></td>
</tr>
</tbody>
</table>
Chemical Synthetic Procedures

Scheme S1. Synthetic route to sulfamoyloxy-linked aminoacyl-AMP analogues. Reagents and conditions: [a] N-hydroxysuccinimide esters a-o, Cs₂CO₃, DMF, rt: 92% (S2a); 53% (S2b); 90% (S2c); 88% (S2d); 77% (S2e); 65% (S2f); 63% (S2g); 75% (S2h); 98% (S2i); 57% (S2j); 66% (S2k); 76% (S2l); 98% (S2m); 78% (S2n); 59% (S2o); [b] 80% aqueous TFA or a mixture of 90:5:5 (v/v) of TFA, H₂O, and TIS, rt: 52% (9); 77% (10); 70% (13); 70% (14); 40% (15); 23% (16); 49% (17); 57% (18); 74% (19); 90% (20); 83% (21); 98% (22); 61% (23); 70% (24); 74% (25).

General Synthetic Methods: All commercial reagents were used as provided unless otherwise indicated. 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (Schemes S1) is known compounds. These compounds were prepared according to published literature procedures. All reactions were carried out under an atmosphere of nitrogen in dry solvents with oven-dried glassware and constant magnetic stirring unless otherwise noted. High performance liquid chromatography (HPLC) was performed on a Prominence CMB-20A (Shimadzu) system equipped with a Prominence SPD-20A UV/VIS detector (Shimadzu). ¹H-NMR spectra were recorded at 500 MHz. ¹³C-NMR spectra were recorded at 125 MHz on JEOL NMR
spectrometers and standardized to the NMR solvent signal as reported by Gottlieb.\(^4\) Multiplicities are given as s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, ddd = doublet of triplets, br = broad signal, m = multiplet using integration and coupling constant in Hertz. TLC analysis was performed using Silica Gel 60 F254 plates (Merck) and visualization was accomplished with ultraviolet light (\(\lambda = 254\) nm) and/or the appropriate stain [phosphomolybdic acid, iodine, ninhydrin, and potassium permanganate]. Silica gel chromatography was carried out with SiliaFlash F60 230-400 mesh (Silicycle), according to the method of Still.\(^5\) Mass spectral data were obtained using a LCMS-IT-TOF mass spectrometer (Shimadzu).

**Chemical Synthesis of Gly-AMS 9**

5′-\([N-(N-Boc-glycyl)sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2a)\)

![Chemical structure of S2a](image)

Boc-Gly-OSu (53 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (90:10:1 CHCl\(_3\)/MeOH/Et\(_3\)N) to afford compound S2a as a white solid (96 mg, 92%). \(^1\)H NMR (500 MHz, DMSO-\(d_6\)) \(\delta\) 8.39 (s, 1H), 8.32 (s, 1H), 8.16 (s, 1H), 7.35 (br, 2H), 6.34 (t, \(J = 5.7\) Hz), 6.16 (d, \(J = 2.9\) Hz), 5.36 (dd, \(J = 6.3, 2.9\) Hz, 1H), 5.01 (dd, \(J = 5.7, 2.3\) Hz, 1H), 4.39–4.36 (m, 1H), 3.99 (dddd, \(J = 22.9, 22.9, 22.9, 5.2\) Hz, 2H), 3.40 (t, \(J = 4.9\) Hz, 2H), 2.88 (q, \(J = 7.4\) Hz, 12H, Et\(_3\)N-\(CH\(_2\)\)), 1.54 (s, 3H), 1.35 (s, 9H), 1.32 (s, 3H), 1.09 (t, \(J = 7.4\) Hz, 18H, Et\(_3\)N-\(CH\(_3\)\)). \(^{13}\)C NMR (125 MHz, DMSO-\(d_6\)) \(\delta\) 173.8, 156.1, 155.5, 152.8, 149.0, 139.5, 118.8, 113.1, 89.2, 83.8, 83.4, 81.6, 79.2, 77.5, 67.0, 45.6, 28.2, 27.0, 25.2, 9.5. HRMS (ESI+): [M+H]\(^+\) calcd for C\(_{29}\)H\(_{29}\)N\(_5\)O\(_9\)S, 544.1820; found, 544.1792.

5′-\([N-(Glycyl)sulfamoyl]-adenosine triethylammonium salt (9)\)
Compound S2a (44 mg, 0.082 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H2O at room temperature. After 10 h, the flask was placed on the rotary evaporator and the TFA and H2O were removed at reduced pressure. The residue was purified by flash chromatography (50:50:1 CHCl3/MeOH/Et3N) to afford compound 9 as a white solid (17 mg, 52%). 1H NMR (500 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.15 (s, 1H), 7.30 (br, 2H), 5.92 (d, J = 6.3 Hz, 1H), 4.60 (t, J = 5.5 Hz, 1H), 4.18–4.14 (m, 2H), 4.11–4.05 (m, 2H), 3.31 (s, 2H), 2.94 (q, J = 7.5 Hz, 1.3H, Et3N-CH2), 1.12 (t, J = 7.5 Hz, 2H, Et3N-CH3). 13C NMR (125 MHz, DMSO-d6) δ 169.8, 156.1, 152.7, 149.6, 139.4, 118.9, 87.0, 82.4, 73.5, 70.7, 67.6, 45.6, 42.7, 9.1. HRMS (ESI+): [M+H]+ calcd for C12H18N7O7S, 404.0983; found, 404.0955.

Chemical Synthesis of L-Ala-AMS 10

5′-O-[N-(N-Boc-L-alanylsulfamoyl)-2′,3′-O-isopropylidenedenosine triethylammonium salt (S2b)

Boc-Ala-OSu (56 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylidenedenosine S1 (50 mg, 0.13 mmol) in DMF (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 CHCl3/MeOH/Et3N) to afford compound S2b as a white solid (39 mg, 53%). 1H NMR (500 MHz, CD3OD) δ 8.46 (s, 1H), 8.22 (s, 1H), 6.23 (d, J = 3.4 Hz, 1H), 5.36 (q, J = 2.9 Hz, 1H), 5.15–5.08 (m, 1H), 4.55–4.50 (m, 1H), 4.26–4.18 (m, 2H), 4.03–3.90 (m, 1H), 3.18 (q, J = 7.5 Hz, 6H, Et3N-CH2), 1.60 (s, 3H), 1.45–1.35 (m, 12H), 1.32–1.22 (m, 12H, Et3N-CH3). 13C NMR (125 MHz, CD3OD) δ 181.4, 157.4, 157.3, 154.0, 150.5, 141.4, 120.1, 115.2, 91.8, 85.7, 85.6, 83.3, 80.0, 69.7, 53.7, 47.8, 28.8, 27.5, 25.6, 19.8, 9.2. HRMS (ESI−): [M−H]− calcd for C21H30N7O9S, 556.1826; found, 556.1833.
**5′-O-N-(L-Alanyl)sulfamoyladenosine triethylammonium salt (10)**

Compound S2b (40 mg, 0.061 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H₂O at room temperature. After 3 h, the flask was placed on the rotary evaporator and the TFA and H₂O were removed at reduced pressure. The residue was purified by flash chromatography (67:33:1 CHCl₃/MeOH/Et₃N to 100:1 MeOH/Et₃N) to afford compound 10 as a white solid (21 mg, 77%). ¹H NMR (500 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.14 (s, 1H), 7.27 (br, 2H), 5.91 (d, J = 5.7 Hz, 1H), 4.60 (t, J = 5.2 Hz, 1H), 4.18−4.12 (m, 2H), 4.11−4.03 (m, 2H), 3.48 (dd, J = 7.5, 6.9 Hz, 1H), 2.73 (q, J = 7.5 Hz, 2H, Et₃N-CH₂), 1.30 (d, J = 7.5 Hz, 3H, Et₃N-CH₃). ¹³C NMR (125 MHz, DMSO-d₆) δ 173.2, 156.0, 152.7, 149.6, 139.4, 118.9, 87.0, 82.5, 73.4, 70.7, 67.6, 50.7, 45.7, 17.2, 10.2. HRMS (ESI−): [M−H]⁻ calcd for C₁₉H₁₈N₇O₇S, 416.0988; found, 416.0983.

**Chemical Synthesis of L-Ile-AMS 13**

5′-O-[N-(N-Boc-L-isoleucyl)sulfamoyl]-2′,3′-O-isopropylidenedadenosine triethylammonium salt (S2c)

Boc-Ile-OSu (64 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylidenedadenosine S1 (50 mg, 0.13 mmol) in DMF (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (90:10:1 CHCl₃/MeOH/Et₃N) to afford compound S2c as a white solid (69 mg, 90%). ¹H NMR (500 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.15 (s, 1H), 7.35 (br, 2H), 6.16 (d, J = 2.9 Hz, 1H), 5.84 (d, J = 8.0 Hz, 1H), 5.34 (dd, J = 5.8, 2.9 Hz, 1H), 5.00 (dd, J = 5.7, 1.7 Hz, 1H), 4.40−4.37 (m, 1H), 4.05−3.98 (m, 2H), 3.66 (dd, J = 8.6, 5.2 Hz, 1H), 2.81 (q, J = 7.5 Hz, 18H, Et₃N-CH₂), 1.75−1.66 (m, 1H), 1.54 (s, 3H), 1.35 (s, 9H), 1.31 (s, 3H), 1.06
(t, J = 7.5 Hz, 27H, Et3-N-CH3), 0.83–0.76 (m, 8H). 13C NMR (125 MHz, DMSO-d6) δ 175.8, 156.1, 155.1, 152.8, 149.0, 139.5, 118.9, 113.2, 89.2, 83.7, 83.5, 81.7, 77.5, 67.2, 60.5, 48.6, 39.2, 28.2, 27.1, 25.2, 24.3, 15.7, 11.7, 9.8. HRMS (ESI+): [M+H]+ calcd for C24H38N7O9S, 600.2446; found, 600.2417.

$5′-O-N-(L$-Isoleucyl)sulfamoyladenosine triethylammonium salt (13)

Compound S2c (30 mg, 0.050 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H2O at room temperature. After 4 h, the flask was placed on the rotary evaporator and the TFA and H2O were removed at reduced pressure. The residue was purified by flash chromatography (50:50:1 CHCl3/MeOH/Et3N) to afford compound 13 as a colorless oil (16 mg, 70%). 1H NMR (500 MHz, CD3OD) δ 8.55 (s, 1H), 8.21 (s, 1H), 6.09 (d, J = 5.2 Hz, 1H), 4.64 (t, J = 5.2 Hz, 1H), 4.41–4.28 (m, 3H), 3.62–3.55 (m, 2H), 3.18 (q, J = 7.5 Hz, 36H, Et3-N-CH2), 1.64–1.55 (m, 1H), 1.32 (t, J = 7.5 Hz, 54H, Et3-N-CH3), 1.04–0.92 (m, 8H). 13C NMR (125 MHz, CD3OD) δ 175.0, 173.1, 150.6, 141.6, 137.6, 120.1, 89.5, 84.3, 79.5, 76.2, 69.0, 61.3, 47.4, 38.1, 25.7, 15.5, 12.2, 9.1. HRMS (ESI+): [M+H]+ calcd for C16H26N7O7S, 460.1614; found, 460.1604.

Chemical Synthesis of L-Asn-AMS 14

$5′-O-[N-(N-Boc-L-asparaginyl(Trt))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2d)

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (182 mg, 0.95 mmol) and N-hydroxysuccinimide (173 mg, 1.56 mmol) were added to a solution of Boc-Asn(Trt)-OH (300 mg, 0.63 mmol) in DMF (6 mL). After 3 h, the reaction mixture was diluted with EtOAc. The mixture was washed with 5% citric acid, 5% NaHCO3, and brine. The organic layer was dried over Na2SO4 and evaporated to dryness. Boc-Asn(Trt)-OSu (155 mg, 0.27 mmol) and cesium
carbonate (176 mg, 0.54 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (70 mg, 0.18 mmol) in DMF (2 mL). The solution was stirred at room temperature for 1 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 to 90:10:1 EtOAc/MeOH/Et₃N) to afford compound S2d as a white solid (150 mg, 88%).

\[ \text{S1} \]

\[ \text{S2d} \]

\[ \text{1}^\text{H NMR (500 MHz, CD₃OD)} \delta 8.42 (s, 1H), 8.21 (s, 1H), 7.27–7.14 (m, 15H), 6.22 (d, \text{J} = 2.9 \text{Hz}, 1H), 5.32–5.27 (m, 1H), 5.09–5.05 (m, 1H), 4.52–4.48 (m, 1H), 4.35–4.28 (m, 1H), 4.23–4.16 (m, 2H), 3.12 (q, \text{J} = 7.5 \text{Hz}, 6H, \text{Et₃N-CH₂}), 2.90–2.81 (m, 1H), 2.70–2.62 (m, 1H), 1.59 (s, 3H), 1.41 (s, 9H), 1.33 (s, 3H), 1.22 (t, \text{J} = 7.5 \text{Hz}, 9H, \text{Et₃N-CH₃}). \]

\[ \text{13}^\text{C NMR (125 MHz, CD₃OD)} \delta 179.4, 172.2, 157.6, 157.3, 154.0, 150.5, 146.0, 141.4, 130.1, 128.7, 127.7, 120.1, 115.2, 91.8, 85.7, 85.6, 83.2, 80.3, 71.6, 69.6, 55.7, 47.8, 41.3, 28.8, 27.5, 25.6, 9.2. \]


**5′-O-N-(L-Asparaginyl)sulfamoyladenosine triethylammonium salt (14)**

Compound S2d (100 mg, 0.12 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H₂O at room temperature. After 2 h, the flask was placed on the rotary evaporator and the TFA and H₂O were removed at reduced pressure. The residue was purified by flash chromatography (90:10:1 to 85:15:1 CHCl₃/MeOH/ET₃N) to afford compound 14 as a white solid (39 mg, 66%).

\[ \text{1}^\text{H NMR (500 MHz, DMSO-d₆)} \delta 8.34 (s, 1H), 8.14 (s, 1H), 7.60 (br, 1H), 7.29 (br, 2H), 7.13 (br, 1H), 5.91 (d, \text{J} = 5.7 \text{Hz}, 1H), 4.58 (t, \text{J} = 5.2 \text{Hz}, 1H), 4.19–4.04 (m, 4H), 3.70 (dd, \text{J} = 9.2, 3.4 \text{Hz}, 1H), 2.81–2.72 (m, 1H, overlapping with \text{Et₃N-CH₂}), 2.45 (dd, \text{J} = 16.6, 9.2 \text{Hz}, 1H), 1.04 (t, \text{J} = 6.9 \text{Hz}, 1.5H, \text{Et₃N-CH₃}). \]

\[ \text{13}^\text{C NMR (500 MHz, DMSO-d₆)} \delta 171.9, 156.0, 152.7, 149.6, 139.4, 118.9, 87.0, 82.4, 73.6, 70.7, 67.5, 51.8, 45.7, 35.5, 10.0. \]


**Chemical Synthesis of L-Gln-AMS 15**

5′-O-[N-(N-Boc-L-glutaminyl(Trt))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2e)
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (240 mg, 1.20 mmol) and N-hydroxysuccinimide (140 mg, 1.20 mmol) were added to a solution of Boc-Gln(Trt)-OH (400 mg, 0.82 mmol) in CH$_2$Cl$_2$ (5 mL). The solution was stirred at room temperature for 5 h. The reaction mixture was evaporated to dryness. The residue was purified by flash chromatography (1:4 to 2:1 EtOAc/hexane) to afford Boc-Gln(Trt)-OSu as a white solid (410 mg, 86%). Boc-Gln(Trt)-OSu (110 mg, 0.19 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (2 mL). The solution was stirred at room temperature for 1 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 to 90:10:1 EtOAc/MeOH/Et$_3$N) to afford compound S2e as a colorless oil (99 mg, 77%). $^1$H NMR (500 MHz, CD$_3$OD) δ 8.48 (s, 1H), 8.21 (s, 1H), 7.30–7.15 (m, 15H), 6.21 (d, $J = 3.5$ Hz, 1H), 5.32 (dd, $J = 6.0, 3.5$ Hz, 1H), 5.09 (dd, $J = 6.0, 1.5$ Hz, 1H), 4.50 (br, 1H), 4.23 (d, $J = 4.0$ Hz, 2H), 4.05 (dd, $J = 6.0, 5.0$ Hz, 1H), 3.06 (q, $J = 7.5$ Hz, 6H, Et$_3$N-CH$_2$), 2.41–2.24 (m, 2H), 2.10–1.94 (m, 1H), 1.94–1.79 (m, 1H), 1.61 (s, 3H), 1.41 (s, 9H), 1.36 (s, 3H), 1.20 (t, $J = 7.5$ Hz, 9H, Et$_3$N-CH$_3$). $^{13}$C NMR (125 MHz, CD$_3$OD) δ 180.0, 174.7, 157.6, 157.3, 154.0, 150.5, 146.0, 141.4, 130.0, 128.7, 127.7, 120.1, 115.2, 91.6, 85.6, 85.4, 83.1, 80.1, 71.5, 69.7, 57.5, 47.7, 34.3, 30.8, 28.8, 27.5, 25.6, 9.4. HRMS (ESI−): [M−H]$^-$ calcld for C$_{42}$H$_{47}$N$_8$O$_{10}$S, 855.3141; found, 855.3157.

5′-O-N-(L-Glutaminyl)sulfamoyladenosine triethylammonium salt (15)

Compound S2e (35 mg, 0.035 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H$_2$O at room temperature. After 30 min, the flask was placed on the rotary evaporator and the TFA and H$_2$O were removed at reduced pressure. The residue was purified by flash chromatography (67:33:1 CHCl$_3$/MeOH/Et$_3$N to MeOH) to afford compound 15 as a white solid (7.5 mg, 40%). $^1$H NMR (500 MHz, CD$_3$OD): δ 8.51 (s, 1H), 8.20 (s, 1H), 6.09 (d, $J = 5.0$ Hz, 1H), 4.63 (t, $J =
5.0 Hz, 1H), 4.41−4.27 (m, 4H), 3.68 (t, \( J = 6.0 \) Hz, 1H), 3.14 (q, \( J = 7.5 \) Hz, 6H, Et\(_3\)N-CH\(_2\) ), 2.47 (t, \( J = 7.0 \) Hz, 2H), 2.18−2.03 (m, 2H), 1.29 (t, \( J = 7.5 \) Hz, 9H, Et\(_3\)N-CH\(_3\) ). \(^{13}\)C NMR (500 MHz, CD\(_3\)OD) \( \delta \) 181.5, 180.5, 157.3, 153.9, 150.8, 141.1, 120.2, 89.3, 84.4, 76.1, 72.2, 69.0, 60.6, 47.9, 30.9, 26.9, 9.2. HRMS (ESI−): [M−H] calcld for C\(_{15}\)H\(_{21}\)N\(_8\)O\(_8\)S, 473.1209; found, 473.1208.

**Chemical Synthesis of L-Ser-AMS 16**

5′-O-[N-(N-Boc-L-seryl(tBu))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2f)

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (160 mg, 0.81 mmol), N-hydroxysuccinimide (94 mg, 0.81 mmol), DIEA (0.35 mL, 2.0 mmol), and DMAP (8.3 mg, 0.068 mmol) were added to a solution of Boc-Ser(tBu)-OH·DCHA (300 mg, 0.68 mmol) in CH\(_2\)Cl\(_2\) (5 mL). The solution was stirred at room temperature for 3 h. The reaction mixture was washed with a 0.1 M HCl solution, saturated NaHCO\(_3\), and brine. The organic layer was dried over Na\(_2\)SO\(_4\) and evaporated to dryness. The residue was purified by flash chromatography (1:9 to 1:2 EtOAc/hexane) to afford Boc-Ser(tBu)-OSu as a white solid (147 mg, 60%). Boc-Ser(tBu)-OSu (70 mg, 0.19 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (2 mL). The solution was stirred at room temperature for 1 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 to 80:20:1 EtOAc/MeOH/Et\(_3\)N) to afford compound S2f as a colorless oil (61 mg, 65%). \(^1\)H NMR (500 MHz, CD\(_3\)OD): \( \delta \) 8.49 (s, 1H), 8.22 (s, 1H), 6.24, (d, \( J = 3.5 \) Hz, 1H), 5.37 (dd, \( J = 5.5, 3.5 \) Hz, 1H), 5.12 (d, \( J = 4.5 \) Hz 1H), 4.54 (dd, \( J = 6.0, 4.0 \) Hz, 1H), 4.27−4.19 (m, 2H), 4.07 (t, \( J = 3.5 \) Hz, 1H), 3.76−3.68 (m, 1H), 3.63 (dd, \( J = 9.5, 3.5 \) Hz, 1H), 3.18 (q, \( J = 7.5 \) Hz, 6H, Et\(_3\)N-CH\(_2\) ), 1.61 (s, 3H), 1.42 (s, 9H), 1.39 (s, 3H), 1.28 (t, \( J = 7.5 \) Hz, 9H, Et\(_3\)N-CH\(_3\) ), 1.12 (s, 9H). \(^{13}\)C NMR (125 MHz, CD\(_3\)OD): \( \delta \) 178.5, 157.5, 157.3, 154.0, 150.5, 141.4, 120.1, 115.2, 91.9, 85.7, 85.5, 83.4, 80.2, 74.3, 69.7, 64.2, 58.6, 47.8, 28.8, 27.8, 27.5, 25.6, 9.2. HRMS (ESI+): [M+H] calcld for C\(_{25}\)H\(_{38}\)N\(_{10}\)O\(_{10}\)S, 630.2552; found, 630.2552.
5′-O-N-(L-Seryl)sulfamoyladenosine triethylammonium salt (16)

Compound S2f (27.4 mg, 0.038 mmol) was dissolved in a 90:5:5 (v/v) mixture of TFA, H₂O, and TIS at room temperature. After 30 min, the flask was placed on the rotary evaporator and the TFA and H₂O were removed at reduced pressure. The residue was purified by flash chromatography (80:20:1 to 50:50:1 CHCl₃/MeOH/Et₃N) to afford compound 16 as a white solid (4.7 mg, 23%).

1H NMR (500 MHz, CD₃OD): δ 8.50 (s, 1H), 8.21 (s, 1H), 6.09 (d, J = 5.0 Hz, 1H), 4.62 (t, J = 5.0 Hz, 1H), 4.43−4.26 (m, 3H), 3.97 (dd, J = 11.5, 4.0 Hz, 1H), 3.93−3.78 (m, 2H), 3.75−3.66 (m, 1H), 3.19 (q, J = 7.5 Hz, 6H, Et₃N-CH₂), 1.30 (t, J = 7.5 Hz, 9H, Et₃N-CH₃).

13C NMR (500 MHz, DMSO-d₆)  δ 170.5, 156.0, 152.7, 149.6, 139.4, 118.9, 87.0, 82.5, 73.5, 70.7, 67.5, 60.8, 57.4, 45.5, 9.9. HRMS (ESI+): [M+H]+ calcd for C₁₃H₂₀N₇O₈S, 434.1089; found, 434.1086.

Chemical Synthesis of L-Thr-AMS 17

5′-O-[N-(N-Boc-L-threonyl(tBu))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2g)

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (170 mg, 0.87 mmol), N-hydroxysuccinimide (100 mg, 0.87 mmol), DIEA (0.38 mL, 2.2 mmol), and DMAP (8.9 mg, 0.073 mmol) were added to a solution of Boc-Thr(tBu)-OH (200 mg, 0.73 mmol) in CH₂Cl₂ (5 mL). The solution was stirred at room temperature for 2 h. The reaction mixture was washed with a 0.1 M HCl solution, saturated NaHCO₃, and brine. The organic layer was dried over Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography (1:5 to 1:2 EtOAc/hexane) to afford Boc-thr(tBu)-OSu as a white solid (220 mg, 82%). Boc-Thr(tBu)-OSu (72 mg, 0.19 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (2 mL).
solution was stirred at room temperature for 1 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 to 80:20:1 EtOAc/MeOH/Et₃N) to afford compound S2g as a white solid (62 mg, 63%). ¹H NMR (500 MHz, CD₃OD): δ 8.49 (s, 1H), 8.22 (s, 1H), 6.23 (d, J = 3.5 Hz, 1H), 5.37 (dd, J = 6.0, 3.5 Hz, 1H), 4.53 (dd, J = 6.0, 3.5 Hz, 1H), 4.18 (dt, J = 6.0, 2.5 Hz, 1H), 3.88 (dd, J = 7.5, 2.5 Hz, 1H), 3.11 (q, J = 7.5 Hz, 6H, Et₃N-CH₂), 1.61 (s, 3H), 1.42 (s, 9H), 1.38 (s, 3H), 1.25 (t, J = 7.5 Hz, 9H, Et₃N-CH₃), 1.16 (s, 9H). ¹³C NMR (125 MHz, CD₃OD): δ 179.2, 158.1, 157.3, 154.0, 150.5, 141.4, 120.1, 115.2, 91.9, 85.7, 85.6, 83.4, 80.2, 74.9, 69.7, 63.4, 47.8, 29.0, 28.8, 27.5, 25.7, 21.9, 9.4. HRMS (ESI+): [M+H]⁺ calcd for C₂₆H₄₀N₇O₁₀S, 642.2563; found, 642.2561.

5′-O-N-(L-Threonyl)sulfamoyladenosine triethylammonium salt (17)

Compound S2g (41 mg, 0.054 mmol) was dissolved in a 90:5:5 (v/v) mixture of TFA, H₂O, and TIS at room temperature. After 30 min, the flask was placed on the rotary evaporator and the TFA and H₂O were removed at reduced pressure. The residue was purified by flash chromatography (90:10:1 to 60:40:1 CHCl₃/MeOH/Et₃N) to afford compound 17 as a white solid (13 mg, 49%). ¹H NMR (500 MHz, CD₃OD): δ 8.51 (s, 1H), 8.19 (s, 1H), 6.08 (d, J = 4.5 Hz, 1H), 4.61 (t, J = 4.5 Hz, 1H), 4.45–4.27 (m, 4H), 4.19 (t, J = 6.0 Hz, 1H), 3.45 (d, J = 4.5 Hz, 1H), 3.13 (q, J = 7.5 Hz, 6H, Et₃N-CH₂), 1.31 (d, J = 6.5 Hz, 3H), 1.28 (t, J = 7.5 Hz, 9H, Et₃N-CH₃), 1.16 (s, 9H). ¹³C NMR (125 MHz, CD₃OD): δ 174.6, 157.2, 153.9, 150.7, 141.2, 120.1, 89.5, 84.2, 76.2, 71.9, 68.9, 67.6, 62.9, 47.8, 21.0, 9.4. HRMS (ESI+): [M+H]⁺ calcd for C₁₄H₂₂N₇O₈S, 448.1245; found, 448.1220.

Chemical Synthesis of L-Met-AMS 18
5′-O-[N-(N-Boc-L-methionyl)sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2h)
Boc-Met-OSu (68 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (94:6:1 EtOAc/MeOH/Et3N) to afford compound S2h as a white solid (80 mg, 75%).

1H NMR (500 MHz, CD3OD) δ 8.47 (s, 1H), 8.22 (s, 1H), 6.23 (d, J = 2.9 Hz, 1H), 5.38−5.33 (m, 1H), 5.14−5.09 (m, 1H), 4.56−4.52 (m, 1H), 4.27−4.22 (m, 2H), 4.11−4.00 (m, 1H), 3.19 (q, J = 7.5 Hz, 6H, Et3N-CH2), 2.53−2.45 (m, 2H), 2.08−2.00 (m, 4H), 1.90−1.80 (m, 1H), 1.61 (s, 3H), 1.44 (s, 9H), 1.39 (s, 3H), 1.29 (t, J = 7.5 Hz, 9H, Et3N-CH3).

13C NMR (125 MHz, CD3OD) δ 180.2, 157.6, 157.3, 154.0, 150.5, 141.4, 120.1, 115.3, 91.8, 85.7, 85.6, 83.3, 80.1, 69.7, 57.4, 47.9, 34.3, 31.2, 28.8, 27.5, 25.6, 15.3, 9.2. HRMS (ESI−): [M−H]− calcd for C23H34N7O9S2, 616.1859; found, 616.1861.

5′-O-(L-Methionyl)sulfamoyladenosine triethylammonium salt (18)

Compound S2h (40 mg, 0.061 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H2O at room temperature. After 3 h, the flask was placed on the rotary evaporator and the TFA and H2O were removed at reduced pressure. The residue was purified by flash chromatography (75:25:1 CHCl3/MeOH/Et3N) to afford compound 18 as a white solid (12 mg, 57%).

1H NMR (500 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.14 (s, 1H), 7.26 (br, 2H), 5.90 (d, J = 5.7 Hz, 1H), 4.59 (t, J = 5.2 Hz, 1H), 4.28−4.23 (m, 2H), 4.11−4.04 (m, 2H), 5.52 (dd, J = 6.9, 5.2 Hz, 1H), 2.64 (q, J = 7.5 Hz, 1.5H, Et3N-CH2), 2.58−2.52 (m, 1H), 2.05−1.98 (m, 4H), 1.91−1.82 (m, 1H), 1.10 (t, J = 7.5 Hz, 2.3H, Et3N-CH3).

13C NMR (125 MHz, DMSO-d6) δ 172.2, 156.0, 152.7, 149.5, 139.4, 118.9, 87.1, 82.4, 73.4, 82.4, 73.4, 70.7, 67.6, 53.8, 45.7, 30.9, 29.0, 14.3, 10.6. HRMS (ESI−): [M−H]− calcd for C15H22N7O7S2, 476.1022; found, 476.1027.
Chemical Synthesis of L-Tyr-AMS 19

5′-O-[N-(N-Boc-L-tyrosyl(tBu)sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2i)

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (127 mg, 0.66 mmol) and N-hydroxysuccinimide (76 mg, 0.66 mmol) were added to a solution of Boc-Tyr(tBu)-OH (100 mg, 0.30 mmol) in CH₂Cl₂ (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was washed with 5% citric acid, 5% NaHCO₃, and brine. The organic layer was dried over Na₂SO₄ and evaporated to dryness to afford Boc-Tyr(tBu)-OSu as a colorless oil (120 mg, 92%). Boc-Tyr(tBu)-OSu (120 mg, 0.28 mmol) and cesium carbonate (293 mg, 0.90 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (58 mg, 0.15 mmol) in DMF (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (90:10:1 CHCl₃/MeOH/Et₃N) to afford compound S2i as a colorless oil (104 mg, 98%).

1H NMR (500 MHz, CD₃OD) δ 8.46 (s, 1H), 8.22 (s, 1H), 7.13 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), 6.24 (d, J = 2.8 Hz, 1H), 5.36 (dd, J = 5.7, 2.9 Hz, 1H), 5.11 (dddd, J = 7.3, 7.3, 7.3, 1.8 Hz, 1H), 4.57–4.49 (m, 1H), 4.24–4.15 (m, 2H), 3.45–3.32 (m, 1H), 3.16 (q, J = 7.5 Hz, 18H, Et₃N-CH₂), 2.89–2.70 (m, 2H), 1.61 (s, 3H), 1.38 (s, 9H), 1.35 (s, 3H), 1.30 (s, 9H), 1.27 (t, J = 7.5, 27H, Et₃N-CH₂).

13C NMR (125 MHz, CD₃OD) δ 178.7, 157.3, 154.8, 154.0, 150.5, 141.4, 134.9, 134.4, 131.0, 124.9, 120.1, 115.2, 91.8, 85.7, 83.2, 79.9, 79.3, 69.7, 58.3, 47.6, 39.2, 29.2, 28.8, 27.5, 25.6, 9.16. HRMS (ESI–): [M–H]⁻ calcd for C₃₁H₄₂N₇O₁₀S, 704.2714; found, 704.2722.

5′-O-(N-Tyrosyl)sulfamoyladenosine triethylammonium salt (19)
Compound S2i (58 mg, 0.082 mmol) was dissolved in a mixture of 90:5:5 (v/v) of TFA, H2O, and TIS at room temperature. After 8 h, the flask was placed on the rotary evaporator, and the TFA and H2O were removed at reduced pressure. The residue was purified by HPLC [COSMISIL 5C18-PAQ: C-18 reverse-phase column, φ 10 mm × 250 mm, acetonitrile/aqueous TFA (0.1%, 10:90), 3.0 mL/min, λ: 220 nm, tR: 12.5 min] to afford compound 19 as a yellow oil (31 mg, 74%).

1H NMR (500 MHz, CD3OD) δ 8.60 (s, 1H), 8.39 (s, 1H), 7.09 (d, J = 8.0 Hz, 2H), 6.70 (d, J = 8.0 Hz, 2H), 6.14 (d, J = 4.6 Hz, 1H), 4.63 (t, J = 4.9 Hz, 1H), 4.44–4.35 (m, 3H), 4.34–4.29 (m, 1H), 3.94 (t, J = 6.3 Hz, 1H), 3.25–3.16 (m, 1H, overlapping with Et3N-CH2), 3.08–2.96 (m, 1H). NMR data were in agreement with published data.6 HRMS (ESI–): [M–H]– calcld for C19H22N7O8S, 508.1251; found, 508.1280.

Chemical Synthesis of L-Trp-AMS 20

5′-O-[N-(N-Boc-L-tryptophanyl(Boc))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2j)

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (230 mg, 1.2 mmol) and N-hydroxysuccinimide (138 mg, 1.2 mmol) were added to a solution of Boc-Trp(Boc)-OH (405 mg, 1.0 mmol) in DMF (10 mL). After 6 h, the reaction mixture was diluted with EtOAc. The mixture was washed with 5% citric acid, 5% NaHCO3, and brine. The organic layer was dried over Na2SO4 and evaporated to dryness. Boc-Trp(Boc)-OSu (98 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (2 mL). The solution was stirred at room temperature for 1 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 to 91:9:1 EtOAc/MEOH/Et3N) to afford compound S2j as a white solid (65 mg, 57%).

1H NMR (500 MHz, CD3OD) δ 8.45 (s, 1H), 8.20 (s, 1H), 8.09–8.00 (m, 1H), 7.72–7.59 (m, 1H), 7.52–7.43 (m, 1H), 7.28–7.13 (m, 2H), 6.21 (d, J = 3.4 Hz, 1H), 5.36–5.27 (m, 1H), 5.12–5.00 (m, 1H), 4.55–4.45 (m, 1H), 4.37–4.11 (m, 3H), 3.28–3.21 (m, 1H), 3.12 (q, J = 7.5 Hz, 6H, Et3N-CH3), 3.04–2.95 (m, 1H), 1.64 (s, 9H), 1.59 (s, 3H), 1.40–1.29 (m, 12H), 1.23 (t, J = 7.5 Hz, 9H, Et3N-CH3). 13C NMR (125 MHz, CD3OD) δ 179.6, 157.3, 154.0, 151.1, 150.5, 141.4, 136.7, 132.4, 125.2, 125.1, 123.5, 120.5, 120.1, 118.1, 115.9, 115.2, 91.8, 85.7, 85.5,

S38
Compound S2j (40 mg, 0.046 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H2O at room temperature. After 3 h, the flask was placed on the rotary evaporator and the TFA and H2O were removed at reduced pressure. The residue was purified by flash chromatography (67:33:1 CHCl3/MeOH/Et3N) to afford compound 20 as a white solid (25 mg, 90%). 1H NMR (500 MHz, DMSO- d6) δ 10.9 (br, 1H), 8.40 (s, 1H), 8.13 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.34 (d, J = 8.6 Hz, 1H), 7.26 (br, 2H), 7.21 (d, J = 2.3 Hz, 1H), 7.07 (dd, J = 8.0, 6.9 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 5.92 (d, J = 5.7 Hz, 1H), 4.64–4.59 (m, 1H), 4.20–4.15 (m, 2H), 4.14–4.05 (m, 2H), 3.67 (dd, J = 8.6, 4.6 Hz, 1H), 3.32 (dd, J = 14.9, 4.0 Hz, 1H), 3.03 (dd, J = 14.9, 8.6 Hz, 1H), 2.57 (q, J = 7.5 Hz, 3H, Et3N-CH2), 0.97 (d, J = 7.5 Hz, 4.5H, Et3N-CH3). 13C NMR (125 MHz, DMSO- d6) δ 172.7, 156.0, 152.7, 149.6, 139.4, 136.3, 127.2, 124.5, 121.0, 118.9, 118.5, 118.3, 111.4, 108.2, 87.1, 82.5, 79.2, 73.5, 70.7, 67.5, 55.7, 45.7, 27.5, 10.9. HRMS (ESI−): [M−H]− calcd for C32H43N8O11S, 771.2772; found, 771.2781.
over Na$_2$SO$_4$ and evaporated to dryness. Boc-Asp(OtBu)-OSu (75 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (2 mL). The solution was stirred at room temperature for 3 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (94:6:1 EtOAc/MeOH/Et$_3$N) to afford compound S2k as a white solid (50 mg, 66%).

$^1$H NMR (500 MHz, CD$_3$OD) δ 8.46 (s, 1H), 8.22 (s, 1H), 6.23 (d, $J = 2.9$ Hz, 1H), 5.38–5.34 (m, 1H), 5.14–5.10 (m, 1H), 4.55–4.52 (m, 1H), 4.33–4.28 (m, 1H), 4.25–4.20 (m, 2H), 3.18 (q, $J = 7.5$ Hz, 6H, Et$_3$N-CH$_2$), 2.75 (dd, $J = 15.5, 5.2$ Hz, 1H), 2.56 (dd, $J = 15.5, 7.5$ Hz, 1H), 1.61 (s, 3H), 1.44–1.37 (m, 21H), 1.28 (t, $J = 7.5$ Hz, 9H, Et$_3$N-CH$_3$).

$^{13}$C NMR (125 MHz, CD$_3$OD) δ 172.4, 157.4, 157.3, 154.0, 150.5, 141.4, 120.1, 115.2, 91.9, 85.7, 85.6, 83.3, 81.9, 80.2, 69.6, 55.0, 47.8, 40.2, 28.8, 28.4, 27.5, 25.6, 9.2. HRMS (ESI−): [M−H$^-$] calcd for C$_{26}$H$_{38}$N$_7$O$_{11}$S, 656.2350; found, 656.2346.

$5′$-O-[(L-Aspartyl)sulfamoyladenosine triethylammonium salt (21)]

Compound S2k (40 mg, 0.053 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H$_2$O at room temperature. After 6 h, the flask was placed on the rotary evaporator and the TFA and H$_2$O were removed at reduced pressure. The residue was purified by flash chromatography (67:33:1 CHCl$_3$/MeOH/Et$_3$N) to afford compound 21 as a white solid (26 mg, 83%). $^1$H NMR (500 MHz, DMSO-$d_6$) δ 8.39 (s, 1H), 8.14 (s, 1H), 7.27 (br, 2H), 5.90 (d, $J = 6.3$ Hz, 1H), 4.60–4.55 (m, 1H), 4.18–4.00 (m, 4H), 3.58–3.54 (m, 1H), 2.86 (q, $J = 7.5$ Hz, 8H, Et$_3$N-CH$_2$), 2.55 (dd, $J = 16.6, 4.0$ Hz, 1H), 2.36 (dd, $J = 16.6, 8.6$ Hz, 1H), 1.08 (t, $J = 7.5$ Hz, 12H, Et$_3$N-CH$_2$). $^{13}$C NMR (125 MHz, DMSO-$d_6$) δ 173.5, 172.3, 156.0, 152.7, 149.6, 139.4, 118.8, 87.0, 82.4, 73.5, 70.6, 67.5, 52.7, 45.4, 36.3, 9.4. HRMS (ESI−): [M−H$^-$] calcd for C$_{14}$H$_{18}$N$_7$O$_9$S, 460.0887; found, 460.0882.

Chemical Synthesis of L-Glu-AMS 22

$5′$-O-[N-(N-Boc-L-glutamyl(tBu))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2I)
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (380 mg, 1.98 mmol) and N-hydroxysuccinimide (228 mg, 1.98 mmol) were added to a solution of Boc-Glu(OtBu)-OH (500 mg, 1.65 mmol) in DMF (16 mL). After 24 h, the reaction mixture was diluted with EtOAc. The mixture was washed with 5% citric acid, 5% NaHCO₃, and brine. The organic layer was dried over Na₂SO₄ and evaporated to dryness. Boc-Glu(OtBu)-OSu (78 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylidenedeoxyadenosine S₁ (50 mg, 0.13 mmol) in DMF (2 mL). The solution was stirred at room temperature for 3 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 to 91:9:1 EtOAc/MeOH/Et₃N) to afford compound S₂₁ as a white solid (76 mg, 76%).

\[
\begin{align*}
\text{HN} & \quad \text{tBu} \\
\text{O} & \quad \text{Et}_3\text{N} \\
\text{NH} & \quad \text{Boc} \\
\text{O} & \quad \text{O} \\
\end{align*}
\]

1H NMR (500 MHz, CD₃OD) δ 8.46 (s, 1H), 8.22 (s, 1H), 6.23 (d, \(J = 2.9\) Hz, 1H), 5.37–5.33 (m, 1H), 5.12–5.08 (m, 1H), 4.56–4.51 (m, 1H), 4.27–4.21 (m, 2H), 4.04–3.97 (m, 1H), 3.18 (q, \(J = 7.5\) Hz, 6H, Et₃N-CH₂), 2.34–3.22 (m, 2H), 2.11–2.01 (m, 1H), 1.89–1.80 (m, 1H), 1.61 (s, 3H), 1.46–1.35 (m, 21H), 1.28 (t, \(J = 7.5\) Hz, 9H, Et₃N-CH₂).

13C NMR (125 MHz, CD₃OD) δ 180.0, 174.3, 157.5, 157.3, 154.0, 150.5, 141.4, 120.1, 115.2, 91.8, 85.7, 85.5, 83.3, 81.4, 80.1, 69.7, 57.4, 47.8, 32.8, 29.8, 28.8, 28.3, 27.5, 25.6, 9.2. HRMS (ESI−): [M−H]⁻ calcd for C₂₇H₄₀N₇O₁₁S, 670.2507; found, 670.2509.

5′-O-N-(L-Glutamyl)sulfamoyladenosine triethylammonium salt (22)

Compound S₂₁ (40 mg, 0.052 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H₂O at room temperature. After 3 h, the flask was placed on the rotary evaporator and the TFA and H₂O were removed at reduced pressure. The residue was purified by flash chromatography (67:33:1 CHCl₃/MeOH/Et₃N to 100:1 MeOH/Et₃N) to afford compound 22 as a white solid (32 mg, 98%).

1H NMR (500 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.14 (s, 1H), 7.26 (br, 2H), 5.90 (d, \(J = 5.7\) Hz, 1H), 4.60–4.57 (m, 1H), 4.17–4.04 (m, 4H), 3.44 (dd, \(J = 6.8, 4.6\) Hz, 1H), 2.70 (q, \(J = 7.5\) Hz, 1H).
\[ = 7.5 \text{ Hz, 9H, Et}_3\text{N-CH}_2, 2.39−2.21 \text{ (m, 2H), 2.00−1.91 \text{ (m, 1H), 1.85−1.77 \text{ (m, 1H), 1.02 (d, } J = 7.5 \text{ Hz, 15H, Et}_3\text{N-CH}_3).} \]
\[ ^{13}\text{C NMR (125 MHz, DMSO-}d_6\text{)} \delta 175.2, 172.6, 156.0, 152.6, 149.6, 139.3, 118.9, 87.0, 82.5, 73.5, 70.7, 67.5, 54.7, 45.5, 32.1, 27.1, 10.2. \]
\[ \text{HRMS (ESI−): [M−H]}^{-} \text{ calcd for C}_{15}\text{H}_{20}\text{N}_7\text{O}_9\text{S, 474.1043.}; \text{ found, 474.1045.} \]

**Chemical Synthesis of L-Lys-AMS 23**

5′-O-[N-(N-Boc-L-lysyl(ε-Boc))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2m)

Boc-Lys(Boc)-OSu (127 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (90:10:1 CHCl\textsubscript{3}/MeOH/Et\textsubscript{3}N) to afford compound S2m as a white solid (106 mg, 98%).

\[ ^{1}\text{H NMR (500 MHz, CD}_3\text{OD) } \delta 8.51 \text{ (s, 1H), 8.21 \text{ (s, 1H), 6.23 (d, } J = 3.4 \text{ Hz, 1H), 5.34 \text{ (dd, } J = 5.7, 3.4 \text{ Hz, 1H), 5.10 \text{ (d, } J = 4.6 \text{ Hz, 1H), 4.56 \text{ (dd, } J = 5.2, 3.5 \text{ Hz, 1H), 4.27−4.20 \text{ (m, 2H), 4.01−3.95 \text{ (m, 1H), 3.14 (q, } J = 7.5 \text{ Hz, 12H, Et}_3\text{N-CH}_2, 3.04−2.99 \text{ (m, 2H), 1.82−1.72 \text{ (m, 2H), 1.61 (s, 3H), 1.49−1.42 \text{ (m, 22H), 1.39 (s, 3H), 1.28 (t, } J = 7.5 \text{ Hz, 18H, Et}_3\text{N-CH}_3).} \]
\[ ^{13}\text{C NMR (125 MHz, CDCl}_3\text{) } \delta 180.9, 158.4, 157.6, 157.6, 157.3, 154.0, 150.4, 120.1, 115.2, 91.7, 85.7, 85.6, 83.2, 80.0, 79.7, 69.7, 58.0, 47.7, 41.1, 34.3, 34.2, 34.1, 30.6, 28.8, 27.5, 25.6, 24.1, 9.32. \]
\[ \text{HRMS (ESI+: [M+H]}^{+} \text{ calcd for C}_{29}\text{H}_{47}\text{N}_8\text{O}_{13}\text{S, 715.3080; found, 715.3039.} \]

5′-O-(N-L-lysyl)sulfamoyladenosine triethylammonium salt (23)

Compound S2m (50 mg, 0.070 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H\textsubscript{2}O at
room temperature. After 10 h, the flask was placed on the rotary evaporator and the TFA and 
H$_2$O were removed at reduced pressure. The residue was purified by HPLC [COSMISIL 5C$_{18}$-
PAQ: C-18 reverse-phase column, $\phi$ 10 mm × 250 mm, aqueous TFA (0.01%), 3.0 mL/min, 220 
nm, $t_R$: 9.5 min] to afford compound 23 as a colorless oil (20 mg, 61%). $^1$H NMR (500 MHz, 
CD$_3$OD) δ 8.63 (s, 1H), 8.41 (s, 1H), 6.14 (d, $J = 4.6$ Hz, 1H), 4.64 (t, $J = 4.9$ Hz, 1H), 
4.47−4.39 (m, 3H), 4.33 (dd, $J = 7.5$, 2.9 Hz, 1H), 3.78 (t, $J = 5.7$ Hz, 1H), 3.21 (q, $J = 7.5$ Hz, 
3H, Et$_3$N-CH$_2$), 2.94 (t, $J = 7.8$ Hz, 2H), 2.00−1.86 (m, 2H), 1.74−1.68 (m, 2H), 1.58−1.49 (m, 
2H), 1.31 (t, $J = 7.5$ Hz, 4.5H, Et$_3$N-CH$_3$).

Chemical Synthesis of L-Arg-AMS 24

5′-O-[N-(N-Boc-L-arginyl (Boc)$_2$)sulfamoyl]-2′,3′-O-isopropylideneadenosine 
triethylammonium salt (S2n)

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (150 mg, 0.76 mmol) and $N$-
hydroxysuccinimide (87 mg, 0.76 mmol) were added to a solution of Boc-Arg(Boc)$_2$-OH (300 
mg, 0.63 mmol) in THF (6 mL) at room temperature. After 15 h, the solvent was evaporated in 
vacuo. The residue was purified by flash chromatography (9:1 to 3:1 EtOAc/hexane) to afford 
Boc-Arg(Boc)$_2$-OSu as a white solid (250 mg, 68%). Boc-Arg(Boc)$_2$-OSu (110 mg, 0.19 mmol) 
and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-
isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (2 mL). The solution was stirred at 
room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. 
The residue was purified by flash chromatography (95:5:1 to 90:10:1 EtOAc/MeOH/Et$_3$N) to 
afford compound S2n as a white solid (99 mg, 78%). $^1$H NMR (500 MHz, CD$_3$OD): δ 8.48 (s, 
1H), 8.22 (s, 1H), 6.23 (d, $J = 3.0$ Hz, 1H), 5.33 (dd, $J = 6.0$, 3.0 Hz, 1H), 5.09 (dd, $J = 5.0$, 3.0 
Hz, 1H), 4.52 (dd, $J = 6.0$, 3.5 Hz, 1H), 4.23 (d, $J = 3.5$ Hz, 2H), 4.04−3.94 (m, 1H), 3.94−3.76 
(m, 3H), 3.17 (q, $J = 7.5$ Hz, 6 H, Et$_3$N-CH$_2$), 1.78 (br, 1H), 1.63 (br, 3H), 1.61 (s, 3H), 1.54 (s, 
3H), 1.51 (s, 9H), 1.46 (s, 9H), 1.44−1.36 (m, 9H), 1.27 (t, $J = 7.5$ Hz, 9H, Et$_3$N-CH$_2$). $^{13}$C 
NMR (125 MHz, CD$_3$OD): δ 180.4, 157.5, 157.3, 156.14, 156.11, 154.0, 150.5, 141.4, 120.1, 
115.3, 91.7, 85.8, 85.5, 85.1, 85.0, 83.2, 80.0, 79.9, 69.7, 57.9, 47.7, 45.8, 31.7, 28.7, 28.7, 28.3,

5′-O-N-(L-arginyl)sulfamoyladenosine (24)

Chemical Synthesis of L-His-AMS 25

5′-O-[N-(N-Boc-L-histidyl(1-Boc))sulfamoyl]-2′,3′-O-isopropylideneadenosine triethylammonium salt (S2o)

Boc-His(Boc)-OSu (88 mg, 0.20 mmol) and cesium carbonate (127 mg, 0.39 mmol) were added to a solution of 5′-O-sulfamoyl-2′,3′-isopropylideneadenosine S1 (50 mg, 0.13 mmol) in DMF (10 mL). The solution was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (95:5:1 to 83:17:1 EtOAc/MeOH/Et_{3}N) to afford compound S2o as a white solid (55 mg, 59%). ¹H NMR (500 MHz, CD_{3}OD) δ 8.47 (s, 1H), 8.52 (s, 1H), 8.20 (s, 1H), 6.09 (d, J = 2.5 Hz, 1H), 4.64 (t, J = 5.0 Hz, 1H), 4.40 (t, J = 4.5 Hz, 1H), 4.36 (dd, J = 11.0, 3.0 Hz, 1H), 4.34–4.27 (m, 2H), 3.34–3.32 (m, 1H), 3.16 (t, J = 6.5 Hz, 2H), 1.82–1.70 (m, 1H), 1.70–1.60 (m, 3H). ¹³C NMR (500 MHz, DMSO-d_{6}) δ 178.6, 156.8, 156.0, 152.6, 149.6, 139.4, 118.8, 86.8, 82.7, 73.7, 70.7, 67.2, 56.1, 40.6, 31.8, 25.2. HRMS (ESI−): [M−H]− calcd for C_{16}H_{25}N_{10}O_{7}S, 501.1634; found, 501.1639.
8.21 (s, 1H), 8.03 (s, 1H), 6.23 (d, $J = 3.4$ Hz, 1H), 5.36–5.31 (m, 1H), 5.11–5.07 (m, 1H),
4.55–4.51 (m, 1H), 4.30–4.19 (m, 3H), 3.18 (q, $J = 7.5$ Hz, 6H, Et$_3$N-CH$_2$), 3.10–3.01 (m, 1H),
2.93–2.85 (m, 1H), 1.61 (s, 3H), 1.58 (s, 9H), 1.39–1.36 (m, 12H), 1.27 (t, $J = 7.5$ Hz, 9H, Et$_3$N-CH$_3$).

$^{13}$C NMR (125 MHz, CD$_3$OD) $\delta$ 179.5, 157.4, 157.3, 154.0, 150.5, 148.2, 141.4,
140.7, 137.8, 120.1, 116.0, 115.2, 91.8, 86.8, 85.7, 85.5, 83.3, 80.1, 69.7, 57.6, 47.8, 32.8, 28.8,
28.6, 28.0, 27.5, 25.6, 9.2. HRMS (ESI−): [M−H]$^-$ calcd for C$_{29}$H$_{40}$N$_9$O$_{11}$S, 722.2568; found,
722.2571.

5′-O-(L-histidyl)sulfamoyladenosine triethylammonium salt (25)

Compound S$_{20}$ (40 mg, 0.061 mmol) was dissolved in a 4:1 (v/v) mixture of TFA and H$_2$O at
room temperature. After 3 h, the flask was placed on the rotary evaporator and the TFA and
H$_2$O were removed at reduced pressure. The residue was purified by flash chromatography
(67:33:1 CHCl$_3$/MeOH/Et$_3$N to 100:1 MeOH/Et$_3$N) to afford compound 25 as a white solid (17
mg, 74%).

$^1$H NMR (500 MHz, DMSO-$d_6$) $\delta$ 8.37 (s, 1H), 8.13 (s, 1H), 7.61 (s, 1H), 7.27 (br, 2H),
6.93 (s, 1H), 5.91 (d, $J = 5.7$ Hz, 1H), 4.62–4.57 (m, 1H), 4.19–4.14 (m, 1H), 4.13–4.07
(m, 2H), 4.04–4.00 (m, 1H), 3.63 (dd, $J = 9.2$, 3.4 Hz, 1H), 3.11 (dd, $J = 14.9$, 3.4 Hz, 1H), 2.81
(dd, $J = 14.9$, 9.2 Hz, 1H), 2.66 (q, $J = 7.5$ Hz, 4H, Et$_3$N-CH$_2$), 1.01 (t, $J = 7.5$ Hz, 6H, Et$_3$N-
CH$_3$). $^{13}$C NMR (125 MHz, DMSO-$d_6$) $\delta$ 171.9, 156.0, 152.7, 149.6, 139.4, 135.0, 118.9, 87.0,
82.5, 73.5, 70.7, 67.4, 55.6, 45.7, 28.7, 10.6. HRMS (ESI−): [M−H]$^-$ calcd for C$_{16}$H$_{21}$N$_9$O$_7$S,
482.1206; found, 482.1212.

Chemical Biology Procedures

Protein Expression and Materials: Recombinant proteins holo-GrsA and holo-TycB1 were
expressed and purified as described previously.$^{7,8,9,10}$ Recombinant holo-GrsA and holo-TycB1
were overproduced and isolated as C-terminal His-tagged constructs using the E. coli
overexpression strain, BL21 (DE3), kindly provided by Prof. Mohamed A. Marahiel at Philipps-
Universität Marburg, Germany.

Hydroxamate-MesG Assay$^1$

Standard assay conditions: Reactions contained holo-GrsA (140–1400 nM) to maintain initial
velocity conditions, 20 mM Tris (pH 8.0), 2.5 mM ATP, 1 mM MgCl$_2$, 1 mM TCEP, 150 mM hydroxylamine (pH 7.0), 0.1 U purine nucleoside phosphorylase (Sigma–Aldrich, N8264), 0.04 U inorganic pyrophosphatase (Sigma–Aldrich, I1643), 0.2 mM MesG (Berry & Associates) and varying concentrations of substrates. The reactions (100 µL) were run in 96-well half-area plates (Corning, 3881) and the cleavage of MesG was monitored at $A_{355}$ on an EnVision Multilabel Reader (PerkinElmer). Working stocks of hydroxylamine were prepared fresh by combining 500 µL of 4 M hydroxylamine, 250 µL of water and 250 µL of 7 M NaOH on ice.

*Determination of kinetic parameters:* Steady-state kinetic parameters of the substrates were determined for holo-GrsA using standard assay conditions as described above. GrsA was used at 700 nM with L-Leu (0.625–10 mM), 1.4 µM with L-Thr (25–300 nM), 140 nM with L-Met (2.5–100 mM), 700 nM with L-Trp (0.125–2.0 mM), and 1.4 µM with L-His (3.125–100 mM). TycB1 was used at 400 nM with L-Pro (10–2000 µM). In all experiments, the total DMSO concentration was kept at or below 2.0%. Initial velocities were fit to the Michaelis-Menten equation using Prism 5 (GraphPad Software).

**Bacterial strains:** *A. migulanus* ATCC 9999 and DSM 5759 were obtained from the American Type Culture Collection (ATCC) and Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), respectively.

**Cultivation media:** YPG media comprises yeast extract (50 g/L), Bacto Peptone (50 g/L), and glucose (5 g/L).$^{11}$

**Preparation of Cellular Lysates for Proteomic Labeling Experiments:** *A. migulanus* ATCC 9999 and DSM 5756 were maintained on nutrient agar. Single colonies were used to inoculate YPG medium and cultures were shaken for 24 h at 37 °C. The seed culture (2 mL) was transferred to YPG media (250 mL) and the resulting mixture was incubated at 37 °C. Growth was routinely monitored at $A_{660}$ on a U-2910 spectrophotometer (Hitachi). The cells were harvested by centrifugation and stored in the freezer until used. The frozen cell pellets were resuspended in Tris pH 8.0 (20 mM), MgCl$_2$ (1 mM), TCEP (1 mM), NP-40 (0.05%), and a protease inhibitor cocktail. Because of the lability of the synthetase during mechanical cell disruption processes,$^{12}$ a gentle treatment of cells with lysozyme (0.2 mg/mL) was used to release intracellular protein. The cell suspension was incubated at 0 °C for 30 min. The mixture was then incubated at 30 °C for 30 min. The solution was centrifuged for 5 min at 15,000 rpm and the pellets were discarded. The total protein concentration was quantitated by the method of Bradford.$^{13}$
Competitive ABPP of the A-domain of endogenous GrsA in a complex proteome: *A. migulanus* ATCC 9999 proteome (2.0 mg/mL) was individually treated with inhibitors 6–25 (100 µM from a 10 mM stock in DMSO) in 20 mM Tris (pH 8.0), 1 mM MgCl₂, 1 mM TCEP, 0.05% NP-40, 0.2 mg/mL lysozyme and the protease inhibitor cocktail. These samples were incubated for 10 min at room temperature and subsequently treated with probe 1 (1 µM from a 100 µM stock in DMSO). In all experiments, the total DMSO concentration was kept at 2.2%. After 10 min at room temperature, these samples were irradiated at 365 nm for 30 min on ice. To initiate the click reaction, rhodamine (Rh)-azide, TCEP, TBTA ligand, and CuSO₄ were added to provide final concentrations of 100 µM, 1 mM, 100 µM, and 1 mM, respectively. After 1 h at room temperature, 5× SDS-loading buffer (strong reducing) was added and the samples were heated at 95 °C for 5 min. Samples were separated by 1D SDS-PAGE and fluorescent gel visualization was performed using a Typhoon 9410 Gel and Blot Imager (GE Healthcare). IC₅₀ values for the A-domain of GrsA were determined from dose–response curves from two trials at each inhibitor concentration (L-Phe-AMS 6: 1 nM to 10 µM; L-Leu-AMS 12: 10 nM to 1 mM; L-Met-AMS 18: 10 nM to 1 mM; L-Trp-AMS 20: 10 nM to 1 mM; L-His-AMS 25: 10 nM to 1 mM; L-Thr-AMS 17: 10 nM to 1 mM; L-Lys-AMS 23: 10 nM to 1 mM) using Prism 5 (GraphPad Software).

Competitive ABPP of the A-domain of recombinant GrsA: Recombinant GrsA (1 µM) were individually treated with inhibitors 6–25 (100 µM from a 10 mM stock in DMSO) in 20 mM Tris (pH 8.0), 1 mM MgCl₂, 1 mM TCEP, and 0.0025% NP-40. These samples were incubated for 10 min at room temperature and subsequently treated with probe 1 (1 µM from a 100 µM stock in DMSO). In all experiments, the total DMSO concentration was kept at 2.2%. After 10 min at room temperature, these samples were irradiated at 365 nm for 30 min on ice and reacted with Rh-azide for 1 h at room temperature. Reactions were treated with 5× SDS-loading buffer (strong reducing) and subjected to SDS-PAGE. Fluorescent gel visualization was performed using a Typhoon 9410 Gel and Blot Imager (GE Healthcare). IC₅₀ values for the A-domain of GrsA were determined from dose–response curves from two trials at each inhibitor concentration (L-Phe-AMS 6: 1 nM to 100 µM; L-Leu-AMS 12: 10 nM to 1 mM; L-Met-AMS 18: 10 nM to 1 mM; L-Trp-AMS 20: 10 nM to 1 mM; L-His-AMS 25: 10 nM to 1 mM; L-Thr-AMS 17: 10 nM to 1 mM; L-Lys-AMS 23: 10 nM to 1 mM) using Prism 5 (GraphPad Software).

Competitive ABPP of the A-domains of endogenous GrsB in a complex proteome: *A. migulanus* DSM 5759 proteome (2.0 mg/mL) was individually treated with inhibitors 6–25 (100 µM from a 10 mM stock in DMSO) in 20 mM Tris (pH 8.0), 1 mM MgCl₂, 1 mM TCEP, 0.05% NP-40, 0.2 mg/mL lysozyme, and the protease inhibitor cocktail. These samples were incubated
for 10 min at room temperature and subsequently treated with individual members of probes 2–5 (1 µM from a 100 µM stock in DMSO). In all experiments, the total DMSO concentration was kept at 2.2%. After 10 min at room temperature, these samples were irradiated at 365 nm for 5 min on ice and reacted with Rh-azide for 1 h at room temperature. Reactions were treated with 5× SDS-loading buffer (strong reducing) and subjected to SDS-PAGE. Fluorescent gel visualization was performed using a Typhoon 9410 Gel and Blot Imager (GE Healthcare). IC$_{50}$ values for the L-Pro activating domain of GrsB were determined from dose–response curves from two trials at various inhibitor concentrations (L-Pro-AMS 7: 0.01 nM to 10 µM; L-Orn-AMS 8: 100 nM to 1 mM; L-Gln-AMS 15: 100 nM to 1 mM). IC$_{50}$ values for the L-Orn activating domain of GrsB were determined from dose–response curves from two trials at each inhibitor concentration (L-Orn-AMS 8: 0.1 pM to 100 nM; L-Gln-AMS 15: 100 nM to 1 mM; L-Lys-AMS 23: 100 nM to 1 mM; L-Arg-AMS 24: 100 nM to 1 mM). IC$_{50}$ values for the L-Val activating domain of GrsB were estimated from dose–response curves from two trials at each inhibitor concentration (L-Val-AMS 11: 0.1 nM to 100 µM; L-Leu-AMS 12: 100 nM to 100 µM; L-Ile-AMS 13: 100 nM to 100 µM; L-Met-AMS 18: 100 nM to 100 µM; L-Trp-AMS 20: 100 nM to 100 µM; L-His-AMS 25: 100 nM to 100 µM). IC$_{50}$ values for the L-Leu activating domain of GrsB were estimated from dose–response curves from two trials at each inhibitor concentration (L-Leu-AMS 12: 0.1 nM to 100 µM; L-Met-AMS 18: 100 nM to 100 µM).

**Competitive ABPP of the A-domain of recombinant TycB1:** Recombinant TycB1 (1 µM) were individually treated with inhibitors 6–25 (100 µM from a 10 mM stock in DMSO) in 20 mM Tris (pH 8.0), 1 mM MgCl$_2$, 1 mM TCEP, and 0.0025% NP-40. These samples were incubated for 10 min at room temperature and subsequently treated with probe 2 (1 µM from a 100 µM stock in DMSO). In all experiments, the total DMSO concentration was kept at 2.2%. After 10 min at room temperature, these samples were irradiated at 365 nm for 30 min on ice and reacted with Rh-azide for 1 h at room temperature. Reactions were treated with 5× SDS-loading buffer (strong reducing) and subjected to SDS-PAGE. Fluorescent gel visualization was performed using a Typhoon 9410 Gel and Blot Imager (GE Healthcare). IC$_{50}$ values for the A-domain of TycB1 were determined from dose–response curves from two trials at each inhibitor concentration (L-Pro-AMS 7: 1 nM to 100 µM; L-Orn-AMS 8: 100 nM to 1 mM; L-Gln-AMS 15: 100 nM to 1 mM) using Prism 5 (GraphPad Software).

**References**

^1H-NMR (500 MHz) and ^13C-NMR (125 MHz) spectra of S2a
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 9
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2b
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 10
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2c
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 13
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2d
$^{1}$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 14
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2e
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 15
\textsuperscript{1}H-NMR (500 MHz) and \textsuperscript{13}C-NMR (125 MHz) spectra of S2f
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 16
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2g
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 17
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2h
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 18
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2i in CD$_3$OD
$^1$H-NMR (500 MHz) spectrum of 19 in CD$_3$OD
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2j
$^{1}$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 20
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2k
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 21
$^{1}$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S21
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 22
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S2m
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 23
\( ^1H\text{-NMR (500 MHz)} \) and \( ^{13}C\text{-NMR (125 MHz)} \) spectra of S2n
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 24
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of S20
$^1$H-NMR (500 MHz) and $^{13}$C-NMR (125 MHz) spectra of 25

![NMR Spectrum](image-url)